Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates

被引:0
|
作者
Von Hoff, Daniel D.
Ervin, Thomas J.
Arena, Francis P.
Chiorean, E. Gabriela
Infante, Jeffrey R.
Moore, Malcolm J.
Seay, Thomas E.
Tjulandin, Sergei
Ma, Wen Wee
Saleh, Mansoor N.
Harris, Marion
Reni, Michele
Ramanathan, Ramesh K.
Tabernero, Josep
Hidalgo, Manuel
Van Cutsem, Eric
Goldstein, David
Wei, Xinyu
Iglesias, Jose Luis
Renschler, Markus Frederic
机构
[1] Scottsdale Healthcare TGen, Virginia G Piper Canc Ctr Clin Trials, Scottsdale, AZ USA
[2] Florida Canc Specialists, Englewood, FL USA
[3] Arena Oncol Associates, Lake Success, NY USA
[4] Univ Washington, Seattle, WA 98195 USA
[5] Sarah Cannon Res Inst, Nashville, TN USA
[6] Tennessee Oncol, Nashville, TN USA
[7] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[8] Atlanta Canc Care, Atlanta, GA USA
[9] Russian Acad Med Sci, NN Blokhin Canc Res Ctr, Moscow, Russia
[10] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
[11] Georgia Canc Specialists PC, Atlanta, GA USA
[12] Southern Hlth, East Bentleigh, Vic, Australia
[13] Univ Milan, Osped San Raffaele, Ist Ricovero & Cura Carattere Sci, I-20127 Milan, Italy
[14] Scottsdale Healthcare TGen, Virginia G Piper Canc Ctr, Scottsdale, AZ USA
[15] Vall dHebron Univ Hosp, Barcelona, Spain
[16] Ctr Integral Oncol Clara Campal, Madrid, Spain
[17] Katholieke Univ Leuven Hosp, Louvain, Belgium
[18] Prince Wales Hosp, Sydney, NSW, Australia
[19] Celgene Corp, Summit, NJ USA
[20] Bionomics Ltd, Thebarton, Australia
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
4005
引用
收藏
页数:1
相关论文
共 50 条
  • [1] Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT)
    Von Hoff, Daniel D.
    Ervin, Thomas J.
    Arena, Francis P.
    Chiorean, E. Gabriela
    Infante, Jeffrey R.
    Moore, Malcolm J.
    Seay, Thomas E.
    Tjulandin, Sergei
    Ma, Wen Wee
    Saleh, Mansoor N.
    Harris, Marion
    Reni, Michele
    Ramanathan, Ramesh K.
    Tabernero, Josep
    Hidalgo, Manuel
    Van Cutsem, Eric
    Goldstein, David
    Wei, Xinyu
    Iglesias, Jose Luis
    Renschler, Markus Frederic
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [2] Updated survival from a randomized phase III trial (MPACT) of nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients (pts) with metastatic adenocarcinoma of the pancreas
    Goldstein, David
    El Maraghi, Robert Hassan
    Hammel, Pascal
    Heinemann, Volker
    Kunzmann, Volker
    Sastre, Javier
    Scheithauer, Werner
    Siena, Salvatore
    Tabernero, Josep
    Teixeira, Luis
    Tortora, Giampaolo
    Van Laethem, Jean-Luc
    Young, Rosemary
    Wei, Xinyu
    Lu, Brian
    Romano, Alfredo
    Von Hoff, Daniel D.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [3] CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer
    Chiorean, E. G.
    Von Hoff, D. D.
    Reni, M.
    Arena, F. P.
    Infante, J. R.
    Bathini, V. G.
    Wood, T. E.
    Mainwaring, P. N.
    Muldoon, R. T.
    Clingan, P. R.
    Kunzmann, V.
    Ramanathan, R. K.
    Tabernero, J.
    Goldstein, D.
    McGovern, D.
    Lu, B.
    Ko, A.
    ANNALS OF ONCOLOGY, 2016, 27 (04) : 654 - 660
  • [4] Prognostic Factors of Survival in a Randomized Phase III Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer
    Tabernero, Josep
    Chiorean, E. Gabriela
    Infante, Jeffrey R.
    Hingorani, Sunil R.
    Ganju, Vinod
    Weekes, Colin
    Scheithauer, Werner
    Ramanathan, Ramesh K.
    Goldstein, David
    Penenberg, Darryl N.
    Romano, Alfredo
    Ferrara, Stefano
    Von Hoff, Daniel D.
    ONCOLOGIST, 2015, 20 (02): : 143 - 150
  • [5] Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas
    Ramanathan, R. K.
    Goldstein, D.
    Korn, R. L.
    Arena, F.
    Moore, M.
    Siena, S.
    Teixeira, L.
    Tabernero, J.
    Van Laethem, J. -L.
    Liu, H.
    McGovern, D.
    Lu, B.
    Von Hoff, D. D.
    ANNALS OF ONCOLOGY, 2016, 27 (04) : 648 - 653
  • [6] Dose delivery in a phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) vs G alone for patients with metastatic adenocarcinoma of the pancreas
    Scheithauer, W.
    Von Hoff, D. D.
    Ramanathan, R. K.
    Moore, M.
    Tabernero, J.
    Goldstein, D.
    Hammel, P.
    Kunzmann, V.
    Ko, A.
    Romano, A.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S614 - S614
  • [7] nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial
    Tehfe, Mustapha
    Dowden, Scot
    Kennecke, Hagen
    El-Maraghi, Robert
    Lesperance, Bernard
    Couture, Felix
    Letourneau, Richard
    Liu, Helen
    Romano, Alfredo
    ADVANCES IN THERAPY, 2016, 33 (05) : 747 - 759
  • [8] nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial
    Mustapha Tehfe
    Scot Dowden
    Hagen Kennecke
    Robert El-Maraghi
    Bernard Lesperance
    Felix Couture
    Richard Letourneau
    Helen Liu
    Alfredo Romano
    Advances in Therapy, 2016, 33 : 747 - 759
  • [9] Positron emission tomography (PET) response from a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) vs G alone for patients (pts) with metastatic adenocarcinoma of the pancreas
    Ramanathan, R. K.
    Von Hoff, D. D.
    Moore, M.
    Teixeira, L.
    Siena, S.
    Tabernero, J.
    Goldstein, D.
    Wei, X.
    Lu, B.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S611 - S611
  • [10] nab-Paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: Australian subset analyses of the phase III MPACT trial
    Young, Rosemary
    Mainwaring, Paul
    Clingan, Philip
    Parnis, Francis Xavier
    Asghari, Gholamreza
    Beale, Philip
    Aly, Abdalla
    Botteman, Marc
    Romano, Alfredo
    Ferrara, Stefano
    Margunato-Debay, Sandra
    Harris, Marion
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 (05) : e325 - e331